Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. That said, here are three stocks where the skepticism is well-placed and some better opportunities to consider.

Doximity (DOCS)

Consensus price target: $31.11 (-5.1% implied return)

With over 80% of U.S. physicians as members of its digital community, Doximity (NYSE: DOCS) operates a digital platform that enables physicians and other healthcare professionals to collaborate, stay current with medical news, manage their careers, and conduct virtual patient visits.

Why Does DOCS Worry Us?

1. Average billings growth of 7.9% over the last year was subpar, suggesting it struggled to push its software and might have to lower prices to stimulate demand
2. Estimated sales growth of 5% for the next 12 months implies demand will slow from its two-year trend
3. Costs have risen faster than its revenue over the last year, causing its operating margin to decline by 10.5 percentage points

Doximity is trading at $32.79 per share, or 9.3x forward price-to-sales. Check out our free in-depth research report to learn more about why DOCS doesn’t pass our bar.

Molson Coors (TAP)

Consensus price target: $43.62 (8.9% implied return)

Sporting an impressive roster of iconic beer brands, Molson Coors (NYSE: TAP) is a global brewing giant with a rich history dating back more than two centuries.

Why Do We Avoid TAP?

1. Falling unit sales over the past two years suggest it might have to lower prices to stimulate growth
2. Expenses have increased as a percentage of revenue over the last year as its operating margin fell by 37 percentage points
3. Below-average returns on capital indicate management struggled to find compelling investment opportunities, and its falling returns suggest its earlier profit pools are drying up

At $40.06 per share, Molson Coors trades at 8.5x forward P/E. Dive into our free research report to see why there are better opportunities than TAP.

Avantor (AVTR)

Consensus price target: $17.35 (8.9% implied return)

With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE: AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries.

Why Do We Think AVTR Will Underperform?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
2. Adjusted operating margin declined by 6.5 percentage points over the last five years as its sales cratered
3. Earnings per share decreased by more than its revenue over the last five years, showing each sale was less profitable

Avantor’s stock price of $15.93 implies a valuation ratio of 19.1x forward P/E. Read our free research report to see why you should think twice about including AVTR in your portfolio.

High-quality stocks for all market conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.